How it works. Psilocybin is a prodrug: the body converts it to psilocin, which binds to serotonin receptors (mainly 5-HT2A) in the brain. Researchers believe it quiets the brain's Default Mode Network, the system behind the repetitive, self-focused thinking often linked with depression and anxiety.

Research highlights. Johns Hopkins, NYU and Imperial College London have published peer-reviewed studies on psilocybin for treatment-resistant depression, end-of-life anxiety and addiction, many showing meaningful improvements after just one to three guided sessions.

The COMPASS Pathways trial. In a large 2022 study, about 29% of people with treatment-resistant depression who received a single guided psilocybin session at the highest tested dose were in remission three weeks later. Fewer were still in remission at three months, which is why researchers see it as a promising start rather than a cure.

Neuroplasticity. Psilocybin appears to boost neuroplasticity, the brain's ability to form new connections, for a short window afterward. That may be part of why the weeks after an experience are often a good time for reflection and habit change.

Important note. This research happens in guided, clinical settings with screening and support. Using mushrooms on your own is a different situation, so start small and respect the experience.